N-[2-(2-benzylanilino)-2-oxoethyl]-1-naphthamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[2-(2-benzylanilino)-2-oxoethyl]-1-naphthamide
• 英文别名: N-[2-(2-benzylanilino)-2-oxoethyl]naphthalene-1-carboxamide
• 化学式: C₂₆H₂₂N₂O₂
• 分子量: 394.5
• InChiKey: NBSHQSJKWMGOTA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Anticancer therapeutic agents
  申请人：RLL, LLC

  公开号：US10420840B2

  公开（公告）日：2019-09-24

  The invention described herein pertains to anticancer therapeutic agents that exhibit preferential cytotoxicity to malignant cells that express a cancer specific isoform of proliferating cell nuclear antigen (caPCNA) compared to cytotoxicity to comparable non-malignant cells, pharmaceutical compositions comprising the agents, and their use in cancer therapy.

  本发明涉及对表达增殖细胞核抗原（caPCNA）癌症特异性异构体的恶性细胞具有优于对同类非恶性细胞的细胞毒性的抗癌治疗剂、包含这些药物的药物组合物及其在癌症治疗中的应用。
• PCNA inhibitors
  申请人：City of Hope

  公开号：US10550070B2

  公开（公告）日：2020-02-04

  Described herein, inter alia, are compositions of PCNA modulators and methods for treating or preventing cancer.

  本文特别描述了 PCNA 调节剂的组合物以及治疗或预防癌症的方法。
• PCNA INHIBITORS
  申请人：City of Hope

  公开号：EP3349754A1

  公开（公告）日：2018-07-25
• ANTICANCER THERAPEUTIC AGENTS
  申请人：RLL, LLC

  公开号：US20160296482A1

  公开（公告）日：2016-10-13

  The invention described herein pertains to anticancer therapeutic agents that exhibit preferential cytotoxicity to malignant cells that express a cancer specific isoform of proliferating cell nuclear antigen (caPCNA) compared to cytotoxicity to comparable non-malignant cells, pharmaceutical compositions comprising the agents, and their use in cancer therapy.
• [EN] ANTICANCER THERAPEUTIC AGENTS<br/>[FR] AGENTS THÉRAPEUTIQUES ANTICANCÉREUX
  申请人：RLL LLC

  公开号：WO2016164707A1

  公开（公告）日：2016-10-13

  The invention described herein pertains to anticancer therapeutic agents that exhibit preferential cytotoxicity to malignant cells that express a cancer specific isoform of proliferating cell nuclear antigen (caPCNA) compared to cytotoxicity to comparable non-malignant cells, pharmaceutical compositions comprising the agents, and their use in cancer therapy.